<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34711805</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>p32 promotes melanoma progression and metastasis by targeting EMT markers, Akt/PKB pathway, and tumor microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>1012</StartPage>
          <MedlinePgn>1012</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1012</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-021-04311-5</ELocationID>
        <Abstract>
          <AbstractText>Melanoma originates from melanin-producing cells called melanocytes. Melanoma poses a great risk because of its rapid ability to spread and invade new organs. Cellular metastasis involves alteration in the gene expression profile and their transformation from epithelial to mesenchymal state. Despite of several advances, metastatic melanoma being a key cause of therapy failure and mortality remains poorly understood. p32 has been found to be involved in various physiological and pathophysiological conditions. However, the role of p32 in melanoma progression and metastasis remains underexplored. Here, we identify the role of p32 in the malignancy of both murine and human melanoma. p32 knockdown leads to reduced cell proliferation, migration, and invasion in murine and human melanoma cells. Furthermore, p32 promotes in vitro tumorigenesis, inducing oncogenes and EMT markers. Mechanistically, we show p32 regulates tumorigenic and metastatic properties through the Akt/PKB signaling pathway in both murine and human melanoma. Furthermore, p32 silencing attenuates melanoma tumor progression and lung metastasis in vivo, modulating the tumor microenvironment by inhibiting the angiogenesis, infiltration of macrophages, and leukocytes in mice. Taken together, our findings identify that p32 drives melanoma progression, metastasis, and regulates the tumor microenvironment. p32 can be a target of a novel therapeutic approach in the regulation of melanoma progression and metastasis.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sinha</LastName>
            <ForeName>Sunita</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6497-9420</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Vascular Immunology, Institute of Life Sciences, Bhubaneswar, 751023, India.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Satyendra Kumar</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Vascular Immunology, Institute of Life Sciences, Bhubaneswar, 751023, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jangde</LastName>
            <ForeName>Nitish</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Vascular Immunology, Institute of Life Sciences, Bhubaneswar, 751023, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ray</LastName>
            <ForeName>Rashmi</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Vascular Immunology, Institute of Life Sciences, Bhubaneswar, 751023, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rai</LastName>
            <ForeName>Vivek</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0003-4539-8916</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Vascular Immunology, Institute of Life Sciences, Bhubaneswar, 751023, India. vivekrai.a@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C087299">C1QBP protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>5</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34711805</ArticleId>
        <ArticleId IdType="pmc">PMC8553772</ArticleId>
        <ArticleId IdType="doi">10.1038/s41419-021-04311-5</ArticleId>
        <ArticleId IdType="pii">10.1038/s41419-021-04311-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA A Cancer J Clin. 2018;68:7–30. doi: 10.3322/caac.21442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21442</ArticleId>
            <ArticleId IdType="pubmed">29313949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136:1161–71. doi: 10.1016/j.jid.2016.01.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jid.2016.01.035</ArticleId>
            <ArticleId IdType="pubmed">26902923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463–82. doi: 10.1038/nrclinonc.2017.43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.43</ArticleId>
            <ArticleId IdType="pubmed">28374786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679–95. doi: 10.1016/j.cell.2006.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.11.001</ArticleId>
            <ArticleId IdType="pubmed">17110329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92. doi: 10.1016/j.cell.2011.09.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.09.024</ArticleId>
            <ArticleId IdType="pmc">PMC3261217</ArticleId>
            <ArticleId IdType="pubmed">22000009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3:362–74. doi: 10.1038/nrc1075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1075</ArticleId>
            <ArticleId IdType="pubmed">12724734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dedio J, Jahnen-Dechent W, Bachmann M, Muller-Esterl W. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein. J Immunol. 1998;160:3534–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9531316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Eguchi T, Aly RG, Chintala NK, Tan KS, Zauderer MG, et al.  Globular C1q receptor (gC1qR/p32/HABP1) is overexpressed in malignant pleural mesothelioma and is associated with increased survival in surgical patients treated with chemotherapy. Front Oncol. 2019;9:1042. doi: 10.3389/fonc.2019.01042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.01042</ArticleId>
            <ArticleId IdType="pmc">PMC6799080</ArticleId>
            <ArticleId IdType="pubmed">31681580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paasonen L, Sharma S, Braun GB, Kotamraju VR, Chung TD, She ZG, et al.  New p32/gC1qR ligands for targeted tumor drug delivery. Chembiochem. 2016;17:570–5. doi: 10.1002/cbic.201500564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbic.201500564</ArticleId>
            <ArticleId IdType="pmc">PMC5433940</ArticleId>
            <ArticleId IdType="pubmed">26895508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peerschke EI, Ghebrehiwet B. The contribution of gC1qR/p33 in infection and inflammation. Immunobiology. 2007;212:333–42. doi: 10.1016/j.imbio.2006.11.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.imbio.2006.11.011</ArticleId>
            <ArticleId IdType="pmc">PMC2001281</ArticleId>
            <ArticleId IdType="pubmed">17544818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peerschke EI, Ghebrehiwet B. cC1qR/CR and gC1qR/p33: observations in cancer. Mol Immunol. 2014;61:100–9. doi: 10.1016/j.molimm.2014.06.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2014.06.011</ArticleId>
            <ArticleId IdType="pubmed">25044096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yenugonda V, Nomura N, Kouznetsova V, Tsigelny I, Fogal V, Nurmemmedov E, et al.  A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma. J Transl Med. 2017;15:210. doi: 10.1186/s12967-017-1312-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-017-1312-7</ArticleId>
            <ArticleId IdType="pmc">PMC5648515</ArticleId>
            <ArticleId IdType="pubmed">29047383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghebrehiwet B, Lim BL, Kumar R, Feng X, Peerschke EI. gC1q-R/p33, a member of a new class of multifunctional and multicompartmental cellular proteins, is involved in inflammation and infection. Immunol Rev. 2001;180:65–77. doi: 10.1034/j.1600-065X.2001.1800106.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1600-065X.2001.1800106.x</ArticleId>
            <ArticleId IdType="pubmed">11414365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen YB, Jiang CT, Zhang GQ, Wang JS, Pang D. Increased expression of hyaluronic acid binding protein 1 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol. 2009;100:382–6. doi: 10.1002/jso.21329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.21329</ArticleId>
            <ArticleId IdType="pubmed">19565630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dembitzer FR, Kinoshita Y, Burstein D, Phelps RG, Beasley MB, Garcia R, et al.  gC1qR expression in normal and pathologic human tissues: differential expression in tissues of epithelial and mesenchymal origin. J Histochem and Cytochem. 2012;60:467–74. doi: 10.1369/0022155412440882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1369/0022155412440882</ArticleId>
            <ArticleId IdType="pmc">PMC3393077</ArticleId>
            <ArticleId IdType="pubmed">22638269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubinstein DB, Stortchevoi A, Boosalis M, Ashfaq R, Ghebrehiwet B, Peerschke EI, et al.  Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells. Int J Cancer. 2004;110:741–50. doi: 10.1002/ijc.20105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.20105</ArticleId>
            <ArticleId IdType="pubmed">15146564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Zhang F, Guo L, Wang Y, Zhang P, Wang R, et al.  Interactome analysis reveals that C1QBP (complement component 1, q subcomponent binding protein) is associated with cancer cell chemotaxis and metastasis. Mol Cell Proteomics. 2013;12:3199–209. doi: 10.1074/mcp.M113.029413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M113.029413</ArticleId>
            <ArticleId IdType="pmc">PMC3820933</ArticleId>
            <ArticleId IdType="pubmed">23924515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prakash M, Kale S, Ghosh I, Kundu GC, Datta K. Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-kappa B dependent MMP-2 activation through integrin α(v)β(3) interaction. Cell Signal. 2011;23:1563–77. doi: 10.1016/j.cellsig.2011.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2011.04.009</ArticleId>
            <ArticleId IdType="pubmed">21627988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leucci E, Vendramin R, Spinazzi M, Laurette P, Fiers M, Wouters J, et al.  Melanoma addiction to the long non-coding RNA SAMMSON. Nature. 2016;531:518–22. doi: 10.1038/nature17161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature17161</ArticleId>
            <ArticleId IdType="pubmed">27008969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Su YJ, Gu PQ, Ji ZY, Wang XG, Gao LJ. The role of the globular heads of C1q receptor (gC1qR) gene in regulating apoptosis of human cervical squamous cell carcinoma. Cell Physiol Biochem. 2012;30:1181–90. doi: 10.1159/000343308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000343308</ArticleId>
            <ArticleId IdType="pubmed">23052251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Yue D, Xiao M, Qi C, Chen Y, Sun D, et al.  C1QBP negatively regulates the activation of oncoprotein YBX1 in the renal cell carcinoma as revealed by interactomics analysis. J Proteome Res. 2015;14:804–13. doi: 10.1021/pr500847p.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/pr500847p</ArticleId>
            <ArticleId IdType="pubmed">25497084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, et al.  Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene. 2017;36:1559–72. doi: 10.1038/onc.2016.324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2016.324</ArticleId>
            <ArticleId IdType="pubmed">27669433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi S, Cordella M, Tabolacci C, Nassa G, D’Arcangelo D, Senatore C, et al.  TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness. J Exp Clin cancer Res. 2018;37:326. doi: 10.1186/s13046-018-0982-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-018-0982-1</ArticleId>
            <ArticleId IdType="pmc">PMC6309098</ArticleId>
            <ArticleId IdType="pubmed">30591049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGee AM, Douglas DL, Liang Y, Hyder SM, Baines CP. The mitochondrial protein C1qbp promotes cell proliferation, migration and resistance to cell death. Cell Cycle. 2011;10:4119–27. doi: 10.4161/cc.10.23.18287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.10.23.18287</ArticleId>
            <ArticleId IdType="pmc">PMC3272292</ArticleId>
            <ArticleId IdType="pubmed">22101277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim BC, Hwang HJ, An HT, Lee H, Park JS, Hong J, et al.  Antibody neutralization of cell-surface gC1qR/HABP1/SF2-p32 prevents lamellipodia formation and tumorigenesis. Oncotarget. 2016;7:49972–85. doi: 10.18632/oncotarget.10267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.10267</ArticleId>
            <ArticleId IdType="pmc">PMC5226562</ArticleId>
            <ArticleId IdType="pubmed">27363031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KB, Yi JS, Nguyen N, Lee JH, Kwon YC, Ahn BY, et al.  Cell-surface receptor for complement component C1q (gC1qR) is a key regulator for lamellipodia formation and cancer metastasis. J Biol Chem. 2011;286:23093–101. doi: 10.1074/jbc.M111.233304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.233304</ArticleId>
            <ArticleId IdType="pmc">PMC3123076</ArticleId>
            <ArticleId IdType="pubmed">21536672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37. doi: 10.1038/nm.3394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3394</ArticleId>
            <ArticleId IdType="pmc">PMC3954707</ArticleId>
            <ArticleId IdType="pubmed">24202395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogal V, Zhang L, Krajewski S, Ruoslahti E. Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res. 2008;68:7210–8. doi: 10.1158/0008-5472.CAN-07-6752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-6752</ArticleId>
            <ArticleId IdType="pmc">PMC2562323</ArticleId>
            <ArticleId IdType="pubmed">18757437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogal V, Richardson AD, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E. Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol. 2010;30:1303–18. doi: 10.1128/MCB.01101-09.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.01101-09</ArticleId>
            <ArticleId IdType="pmc">PMC2832503</ArticleId>
            <ArticleId IdType="pubmed">20100866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat. 2007;104:13–9. doi: 10.1007/s10549-006-9392-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-006-9392-8</ArticleId>
            <ArticleId IdType="pubmed">17004106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nerlich AG, Bachmeier BE. Density-dependent lineage instability of MDA-MB-435 breast cancer cells. Oncol Lett. 2013;5:1370–4. doi: 10.3892/ol.2013.1157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2013.1157</ArticleId>
            <ArticleId IdType="pmc">PMC3629269</ArticleId>
            <ArticleId IdType="pubmed">23599796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 2009;69:5292–3. doi: 10.1158/0008-5472.CAN-09-1528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-1528</ArticleId>
            <ArticleId IdType="pubmed">19549886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peerschke E, Stier K, Li X, Kandov E, de Stanchina E, Chang Q, et al.  gC1qR/HABP1/p32 is a potential new therapeutic target against mesothelioma. Front Oncol. 2020;10:1413. doi: 10.3389/fonc.2020.01413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.01413</ArticleId>
            <ArticleId IdType="pmc">PMC7435067</ArticleId>
            <ArticleId IdType="pubmed">32903438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noh S, Phorl S, Naskar R, Oeum K, Seo Y, Kim E, et al.  p32/C1QBP regulates OMA1-dependent proteolytic processing of OPA1 to maintain mitochondrial connectivity related to mitochondrial dysfunction and apoptosis. Sci Rep. 2020;10:10618. doi: 10.1038/s41598-020-67457-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-67457-w</ArticleId>
            <ArticleId IdType="pmc">PMC7327069</ArticleId>
            <ArticleId IdType="pubmed">32606429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carver EA, Jiang R, Lan Y, Oram KF, Gridley T. The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition. Mol Cell Biol. 2001;21:8184–8. doi: 10.1128/MCB.21.23.8184-8188.2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.21.23.8184-8188.2001</ArticleId>
            <ArticleId IdType="pmc">PMC99982</ArticleId>
            <ArticleId IdType="pubmed">11689706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai M, Al-Odaini AA, Fils-Aime N, Villatoro MA, Guo J, Arakelian A, et al.  Cyclin D1 cooperates with p21 to regulate TGFbeta-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Res. 2013;15:R49. doi: 10.1186/bcr3441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr3441</ArticleId>
            <ArticleId IdType="pmc">PMC4053239</ArticleId>
            <ArticleId IdType="pubmed">23786849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Mancera PA, Gonzalez-Herrero I, Perez-Caro M, Gutierrez-Cianca N, Flores T, Gutierrez-Adan A, et al.  SLUG in cancer development. Oncogene. 2005;24:3073–82. doi: 10.1038/sj.onc.1208505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1208505</ArticleId>
            <ArticleId IdType="pubmed">15735690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al.  Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927–39. doi: 10.1016/j.cell.2004.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2004.06.006</ArticleId>
            <ArticleId IdType="pubmed">15210113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, et al.  Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. Oncotarget. 2015;6:1157–70. doi: 10.18632/oncotarget.2708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.2708</ArticleId>
            <ArticleId IdType="pmc">PMC4359224</ArticleId>
            <ArticleId IdType="pubmed">25528767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavoni G, Gabriele L, Mattei F. The tumor microenvironment: a pitch for multiple players. Front Oncol. 2013;3:90. doi: 10.3389/fonc.2013.00090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2013.00090</ArticleId>
            <ArticleId IdType="pmc">PMC3628362</ArticleId>
            <ArticleId IdType="pubmed">23616948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulmann-Leal B, Ellwanger JH, Chies JAB. A functional interaction between the CCR5 and CD34 molecules expressed in hematopoietic cells can support (or even promote) the development of cancer. Hematol. Transfus Cell Ther. 2020;42:70–6. doi: 10.1016/j.htct.2019.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.htct.2019.10.001</ArticleId>
            <ArticleId IdType="pmc">PMC7031097</ArticleId>
            <ArticleId IdType="pubmed">31822447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nielsen SR, Schmid MC. Macrophages as key drivers of cancer progression and metastasis. Mediators Inflamm. 2017;2017:9624760. doi: 10.1155/2017/9624760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/9624760</ArticleId>
            <ArticleId IdType="pmc">PMC5292164</ArticleId>
            <ArticleId IdType="pubmed">28210073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh S, Mehta N, Lilan J, Budhthoki MB, Chao F, Yong L. Initiative action of tumor-associated macrophage during tumor metastasis. Biochim Open. 2017;4:8–18. doi: 10.1016/j.biopen.2016.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopen.2016.11.002</ArticleId>
            <ArticleId IdType="pmc">PMC5801826</ArticleId>
            <ArticleId IdType="pubmed">29450136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vichalkovski A, Gresko E, Hess D, Restuccia DF, Hemmings BA. PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene. 2010;29:3554–65. doi: 10.1038/onc.2010.115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2010.115</ArticleId>
            <ArticleId IdType="pubmed">20400976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henderson V, Smith B, Burton LJ, Randle D, Morris M, Odero-Marah VA. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression. Cell Adhes Migr. 2015;9:255–64. doi: 10.1080/19336918.2015.1013383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19336918.2015.1013383</ArticleId>
            <ArticleId IdType="pmc">PMC4594564</ArticleId>
            <ArticleId IdType="pubmed">26207671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray R, Sinha S, Aidinis V, Rai V. Atx regulates skeletal muscle regeneration via LPAR1 and promotes hypertrophy. Cell Rep. 2021;34:108809. doi: 10.1016/j.celrep.2021.108809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2021.108809</ArticleId>
            <ArticleId IdType="pubmed">33657371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahimi H, Salehiabar M, Barsbay M, Ghaffarlou M, Kavetskyy T, Sharafi A, et al.  CRISPR systems for COVID-19 diagnosis. ACS Sensors. 2021;6:1430–45. doi: 10.1021/acssensors.0c02312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acssensors.0c02312</ArticleId>
            <ArticleId IdType="pmc">PMC7860143</ArticleId>
            <ArticleId IdType="pubmed">33502175</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
